148 related articles for article (PubMed ID: 33677043)
1. Differential expression of hydroxyurea transporters in normal and polycythemia vera hematopoietic stem and progenitor cell subpopulations.
Tan G; Meier-Abt F
Exp Hematol; 2021 May; 97():47-56.e5. PubMed ID: 33677043
[TBL] [Abstract][Full Text] [Related]
2. Proteomic identification of proliferation and progression markers in human polycythemia vera stem and progenitor cells.
Tan G; Wolski WE; Kummer S; Hofstetter M; Theocharides APA; Manz MG; Aebersold R; Meier-Abt F
Blood Adv; 2022 Jun; 6(11):3480-3493. PubMed ID: 35008095
[TBL] [Abstract][Full Text] [Related]
3. Circulating hematopoietic progenitor cells in polycythemia vera: the in vivo effect of hydroxyurea.
Castello G; Lerza R; Cerruti A; Cavallini D; Bogliolo G; Pannacciulli I
Ann Hematol; 1995 Sep; 71(3):119-21. PubMed ID: 7548329
[TBL] [Abstract][Full Text] [Related]
4. Hydroxyurea treatment reduces haematopoietic progenitor growth and CD34 positive cells in polycythaemia vera and essential thrombocythaemia.
Andréasson B; Swolin B; Kutti J
Eur J Haematol; 2000 Mar; 64(3):188-93. PubMed ID: 10997885
[TBL] [Abstract][Full Text] [Related]
5. Elevated nuclear factor erythroid-2 levels promote epo-independent erythroid maturation and recapitulate the hematopoietic stem cell and common myeloid progenitor expansion observed in polycythemia vera patients.
Bogeska R; Pahl HL
Stem Cells Transl Med; 2013 Feb; 2(2):112-7. PubMed ID: 23341442
[TBL] [Abstract][Full Text] [Related]
6. ABCG2 Is Overexpressed on Red Blood Cells in Ph-Negative Myeloproliferative Neoplasms and Potentiates Ruxolitinib-Induced Apoptosis.
Buks R; Brusson M; Cochet S; Galochkina T; Cassinat B; Nemazanyy I; Peyrard T; Kiladjian JJ; de Brevern AG; Azouzi S; El Nemer W
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33805426
[TBL] [Abstract][Full Text] [Related]
7. Sustained enhancement of OCTN1 transporter expression in association with hydroxyurea induced γ-globin expression in erythroid progenitors.
Walker AL; Ofori-Acquah SF
Exp Hematol; 2017 Jan; 45():69-73.e2. PubMed ID: 27616638
[TBL] [Abstract][Full Text] [Related]
8. Hydroxyurea (HU) is effective in reducing JAK2V617F mutated clone size in the peripheral blood of essential thrombocythemia (ET) and polycythemia vera (PV) patients.
Spanoudakis E; Bazdiara I; Kotsianidis I; Margaritis D; Goutzouvelidis A; Christoforidou A; Tsatalas C; Bourikas G
Ann Hematol; 2009 Jul; 88(7):629-32. PubMed ID: 19096846
[TBL] [Abstract][Full Text] [Related]
9. Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea.
Tutaeva V; Misurin AV; Michiels JJ; Rozenberg JM; Sokolova MA; Ivanova VL; Kolosheinova TI; Manakova TE; Levina AA; Semenova EA; Khoroshko ND
Hematology; 2007 Dec; 12(6):473-9. PubMed ID: 17852451
[TBL] [Abstract][Full Text] [Related]
10. Genomic characterization of patients with polycythemia vera developing resistance to hydroxyurea.
Alvarez-Larrán A; Díaz-González A; Such E; Mora E; Andrade-Campos M; García-Hernández C; Gómez-Casares MT; García-Gutiérrez V; Carreño-Tarragona G; Garrote M; Fernández-Ibarrondo L; Cervera J; Bellosillo B; Cervantes F; Hernández-Boluda JC;
Leukemia; 2021 Feb; 35(2):623-627. PubMed ID: 32372025
[No Abstract] [Full Text] [Related]
11. Reduced CXCL4/PF4 expression as a driver of increased human hematopoietic stem and progenitor cell proliferation in polycythemia vera.
Meier-Abt F; Wolski WE; Tan G; Kummer S; Amon S; Manz MG; Aebersold R; Theocharides APA
Blood Cancer J; 2021 Feb; 11(2):31. PubMed ID: 33574218
[No Abstract] [Full Text] [Related]
12. Differential expression of JAK2 and Src kinase genes in response to hydroxyurea treatment in polycythemia vera and essential thrombocythemia.
Albizua E; Gallardo M; Barrio S; Rapado I; Jimenez A; Ayala R; Rueda D; Sanchez-Espiridion B; Puigdecanet E; Espinet B; Florensa L; Besses C; Martinez-Lopez J
Ann Hematol; 2011 Aug; 90(8):939-46. PubMed ID: 21331593
[TBL] [Abstract][Full Text] [Related]
13. [Recent advances in polycythemia vera treatment].
Edahiro Y
Rinsho Ketsueki; 2020; 61(9):1187-1194. PubMed ID: 33162515
[TBL] [Abstract][Full Text] [Related]
14. Increased erythropoiesis in polycythemia vera is associated with increased erythroid progenitor proliferation and increased phosphorylation of Akt/PKB.
Dai C; Chung IJ; Krantz SB
Exp Hematol; 2005 Feb; 33(2):152-8. PubMed ID: 15676208
[TBL] [Abstract][Full Text] [Related]
15. Polycythemia vera and hydroxyurea resistance/intolerance: a monocentric retrospective analysis.
Demuynck T; Verhoef G; Delforge M; Vandenberghe P; Devos T
Ann Hematol; 2019 Jun; 98(6):1421-1426. PubMed ID: 30919072
[TBL] [Abstract][Full Text] [Related]
16. Addiction to DUSP1 protects JAK2V617F-driven polycythemia vera progenitors against inflammatory stress and DNA damage, allowing chronic proliferation.
Stetka J; Vyhlidalova P; Lanikova L; Koralkova P; Gursky J; Hlusi A; Flodr P; Hubackova S; Bartek J; Hodny Z; Divoky V
Oncogene; 2019 Jul; 38(28):5627-5642. PubMed ID: 30967632
[TBL] [Abstract][Full Text] [Related]
17. Comparative long-term effects of interferon α and hydroxyurea on human hematopoietic progenitor cells.
King KY; Matatall KA; Shen CC; Goodell MA; Swierczek SI; Prchal JT
Exp Hematol; 2015 Oct; 43(10):912-918.e2. PubMed ID: 26072330
[TBL] [Abstract][Full Text] [Related]
18. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Nand S; Stock W; Godwin J; Fisher SG
Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
[TBL] [Abstract][Full Text] [Related]
19. Second line therapies in polycythemia vera: What is the optimal strategy after hydroxyurea failure?
Nazha A; Khoury JD; Verstovsek S; Daver N
Crit Rev Oncol Hematol; 2016 Sep; 105():112-7. PubMed ID: 27401783
[TBL] [Abstract][Full Text] [Related]
20. In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2 V617F allele.
Gaikwad A; Nussenzveig R; Liu E; Gottshalk S; Chang K; Prchal JT
Exp Hematol; 2007 Apr; 35(4):587-95. PubMed ID: 17379069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
